Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7Q9 | ISIN: BE0974260896 | Ticker-Symbol: 1C0
München
05.09.25 | 08:02
0,280 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CELYAD ONCOLOGY SA Chart 1 Jahr
5-Tage-Chart
CELYAD ONCOLOGY SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,2660,34606.09.

Aktuelle News zur CELYAD ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCelyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)244Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that 3,849,040 registered shares benefit from a double voting right as of September 4, 2025. As a...
► Artikel lesen
26.08.Celyad Oncology SA: Celyad Oncology Announces Discontinuation of R&D Activities191Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that it has decided to discontinue its research and development (R&D) activities and to implement...
► Artikel lesen
13.08.Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC278(Article 14 §1 of the Law of 2 May 2007) Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announces, in accordance with Article 14 of the Belgian...
► Artikel lesen
07.08.Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)459Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announces the below information following the issuance, on August 5, 2025, of 3,333,333 new shares...
► Artikel lesen
CELYAD ONCOLOGY Aktie jetzt für 0€ handeln
30.07.XFRA 1C0: WIEDERAUFNAHME/RESUMPTION215FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
28.07.Celyad Oncology SA: Celyad Oncology Announces €1 Million Private Placement301Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") today announced that it has entered into a subscription agreement for a private placement financing. Under the terms...
► Artikel lesen
28.07.XFRA 1C0: AUSSETZUNG/SUSPENSION260DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCELYAD ONCOLOGY...
► Artikel lesen
24.06.Celyad Oncology SA: Celyad Oncology Announces Strategic Review326Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company" or "Celyad") today announced that it is conducting a comprehensive review of strategic alternatives....
► Artikel lesen
02.04.Celyad Oncology SA GAAP EPS of -€0.14, revenue of €0.2M1
02.04.Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights492Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update. Matt Kane...
► Artikel lesen
18.02.Celyad Oncology SA: Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform556 Regulatory News: Celyad Oncology (Euronext: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces the publication of the preclinical data of the non-gene edited allogeneic...
► Artikel lesen
07.10.24Celyad Oncology SA: Celyad Oncology to Present at the 2024 SITC Annual Meeting549Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces two poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held...
► Artikel lesen
16.09.24Celyad Oncology SA: Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer912Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") is pleased to announce Matt Kane as its new Chief Executive Officer (CEO), effective as of October 1st, 2024. Matt...
► Artikel lesen
13.09.24Celyad Oncology SA: Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights471The Company continues to bolster its intellectual property estate and to pursue options to monetize it The Company's two main research and development platforms have delivered proof-of-concept...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1